Key result
R403Q-MyHC but not R92W-TnT mutants exhibit an energy-deficient cardiac phenotype reflecting allele-specific metabolic remodeling.
Why the study?
It is unknown whether all sarcomeric protein gene mutations in hypertrophic cardiomyopathy cause similar derangements of cardiac energy metabolism.
Do R403Q-MyHC and R92W-TnT hypertrophic cardiomyopathy mutations cause allele-specific impairments in cardiac substrate utilization and energy reserves in mouse hearts?
Do R403Q-MyHC and R92W-TnT hypertrophic cardiomyopathy mutations cause allele-specific impairments in cardiac substrate utilization and energy reserves in mouse hearts?
Demonstrates that cardiac energy metabolism remodeling in hypertrophic cardiomyopathy is allele-specific (present in R403Q-MyHC but not R92W-TnT mice), suggesting metabolic therapies may have mutation-specific efficacy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for mutation-specific metabolic therapies in HCM; leaves open translation beyond these mouse models.
Background and Hypothesis: Hypertrophic cardiomyopathy (HCM) is considered a metabolic disease, but it is unknown whether all sarcomeric protein gene mutations lead to similar derangements of cardiac energy metabolism. Our prior studies showing differences in mitochondrial function in mouse models led us to hypothesize that HCM mutations lead to allele-specific metabolic pathway remodeling. In order to test this hypothesis, we examined cardiac substrate utilization using a triple tracer approach that simultaneously assays fatty acid (FA), ketone, and glucose oxidation, in R403Q-MyHC and R92W-TnT perfused hearts at established disease stage. Methods: Mouse hearts (14–16 weeks old) were Langendorff-perfused to steady state 13C enrichment (~30 min) while placed in a 14.1 T NMR for in situ 31P spectroscopy. The perfusate contained substrates which each produce distinctively labeled acetyl-CoA: [1,6-13C2]glucose, [U-13C]mixed fatty acids, and [1,3-13C2]β-hydroxybutyrate. At the end of perfusion, hearts were freeze clamped and extracted for 13C NMR isotopomer analysis. Oxygen concentration in afferent/efferent perfusate was measured using a Clark electrode, and used to compute myocardial oxygen consumption rate (MVO2). Results: Using a model of citric acid cycle (CAC) metabolism that equates MVO2 with production of reducing equivalents, we observed significantly lower fatty acid (FA) oxidation and pyruvate dehydrogenase (PDH) flux in MyHC mutants, but similar substrate utilization in TnT mutants, when compared to respective controls. 31P-spectroscopy revealed significantly lower energy reserves reflected by lower PCr/ATP ratios in MyHC mutants, but similar PCr/ATP ratios in TnT mutants compared to controls. Conclusion: Cardiac metabolic flux measurements revealed an energy-deficient cardiac phenotype in R403Q-MyHC mutants, but not R92W-TnT mutants, reflecting allele-specific remodeling of cardiac energy metabolism. These results suggest that therapeutics aimed at downregulation of FA or carbohydrate metabolism may have mutation-specific effects.
No takes yet. Share an insight, caveat, or question.
Ragavan et al. (2026) studied Hypertrophic cardiomyopathy (HCM). R403Q-MyHC and R92W-TnT sarcomeric mutations assayed via triple 13C-tracer Langendorff perfusion ([1,6-13C2]glucose, [U-13C]mixed fatty acids, [1,3-13C2]β-hydroxybutyrate) vs. Respective control mouse hearts was evaluated on Cardiac substrate utilization (fatty acid oxidation and pyruvate dehydrogenase flux) and energy reserves (PCr/ATP ratios). R403Q-MyHC mutant mouse hearts showed significantly lower fatty acid oxidation, pyruvate dehydrogenase flux, and PCr/ATP ratios vs controls, whereas R92W-TnT mutants had similar levels.
Synapse has enriched 10 related papers. Consider them for comparative context: